Biofrontera Inc. Faces Delisting Notice, Enters New Agreement

TL;DR

BFRI got a delisting warning AND signed a new deal. Big uncertainty ahead.

AI Summary

On November 21, 2024, Biofrontera Inc. entered into a material definitive agreement related to a direct financial obligation. The company also issued a notice of delisting or failure to satisfy a continued listing rule, indicating potential issues with its stock exchange listing. The filing includes financial statements and exhibits.

Why It Matters

This filing signals potential financial distress or compliance issues for Biofrontera Inc., which could significantly impact its stock value and operational stability.

Risk Assessment

Risk Level: high — The notice of delisting and the entry into a new financial obligation suggest significant financial or operational challenges for Biofrontera Inc.

Key Players & Entities

• Biofrontera Inc. (company) — Registrant
• November 21, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share BFRI The Nasdaq Stock Mar
• $4,200,000 — ivate Placement ") to the Purchasers of $4,200,000 in aggregate principal amount of the Co
• $0.78 — Stock at an initial conversion price of $0.78 per share, subject to customary adjustm
• $2 — Common Stock on Nasdaq is greater than $2.50, and certain other conditions are me
• $0 — ased on the initial conversion price of $0.78, which is subject to customary anti-

Filing Documents

• form8-k.htm (8-K) — 60KB
• ex4-1.htm (EX-4.1) — 203KB
• ex10-1.htm (EX-10.1) — 456KB
• ex10-2.htm (EX-10.2) — 285KB
• 0001493152-24-047928.txt ( ) — 1417KB
• bfri-20241121.xsd (EX-101.SCH) — 4KB
• bfri-20241121_def.xml (EX-101.DEF) — 30KB
• bfri-20241121_lab.xml (EX-101.LAB) — 36KB
• bfri-20241121_pre.xml (EX-101.PRE) — 27KB
• form8-k_htm.xml (XML) — 6KB

01 Entry into

Item 1.01 Entry into a Material Definitive Agreement. On November 21, 2024, Biofrontera Inc., a Delaware corporation (the " Company "), entered into a Securities Purchase Agreement (the " Purchase Agreement ") with its principal stockholders (the " Purchasers ") providing for the private placement (the " Private Placement ") to the Purchasers of $4,200,000 in aggregate principal amount of the Company's 10.0% Senior Secured Convertible Notes due November 22, 2027 (the " Notes "). The closing of the Private Placement occurred on November 22, 2024 (the " Closing Date "). The Notes bear interest at 10.0% per annum, payable quarterly in arrears on January 15, April 15, July 15 and October 15 of each year, commencing on January 15, 2025. Accrued interest on the Notes is paid on each such quarterly scheduled interest payment date by increasing the outstanding principal amount of the Notes in the amount of the interest accrued for the applicable interest period ending on such date and from and after such date interest shall accrue on the aggregate outstanding principal amount so increased. Upon written notice from the holder of the Notes to the Company that an Event of Default (as defined in the Notes) has occurred and is continuing, the interest will increase to 15% per annum from the date of such notice. The Notes mature on November 22, 2027, unless earlier converted or repurchased. The Company may not redeem the Notes at its option prior to maturity. Upon maturity, the Company will pay to the holders of the Notes an amount in cash representing all of the outstanding aggregate principal amount of the Notes, together with any accrued and unpaid interest. The Notes may be converted at any time by the noteholder to shares of Common Stock at an initial conversion price of $0.78 per share, subject to customary adjustments for stock splits, stock dividends and recapitalizations, as described in the Notes. Alternatively, the entire amount of the note will be automaticall

View Full Filing

View this 8-K filing on SEC EDGAR